1990-2019年75个流行国家伤寒与甲型副伤寒沙门菌感染抗菌药物耐药亚国家流行率的模型研究
该研究采用贝叶斯时空模型,估算1990-2019年75个流行国家1403个行政一区 districts 中伤寒与甲型副伤寒沙门菌的多重耐药、氟喹诺酮类不敏感和第三代头孢菌素耐药的流行率。整合601个来源、184225株分离株数据,发现撒哈拉以南非洲多重耐药伤寒流行率从1990年6.0%升至2019年72.7%,南亚氟喹诺酮类不敏感率达95.2%。
要点
- 撒哈拉以南非洲多重耐药伤寒流行率从1990年6.0%升至2019年72.7%
- 南亚氟喹诺酮类不敏感伤寒2019年达95.2%
- 巴基斯坦第三代头孢菌素耐药伤寒2019年达61.0%
核心结论
- 研究提供了1990-2019年流行国家伤寒与甲型副伤寒沙门菌多重耐药、氟喹诺酮类不敏感和第三代头孢菌素耐药流行率的全面分析。
- 分析强调这一可预防感染的抗菌药物耐药水平不断上升,可作为指导紧急公共卫生干预(如改善水、环境卫生和个人卫生以及伤寒疫苗接种活动)的资源。
研究设计与样本
- 采用贝叶斯时空模型框架,估算1990-2019年75个流行国家1403个行政一区 district 中伤寒与甲型副伤寒沙门菌多重耐药、氟喹诺酮类不敏感和第三代头孢菌素耐药的百分比。
- 整合来自全面系统综述、公共卫生监测网络和大型多国伤寒研究的数据,共汇集601个来源、184225株伤寒与甲型副伤寒沙门菌分离株,覆盖45个国家、30年。
- 基于全球疾病负担研究的伤寒发病率估计,生成国家、超级区域和总流行区域水平的耐药流行率及耐药感染数估计。
主要发现
- 南亚和东南亚多重耐药伤寒下降,而撒哈拉以南非洲总体流行率从1990年6.0%(95%不确定性区间4.3-8.0)升至2019年72.7%(67.7-77.3)。
- 氟喹诺酮类不敏感伤寒从1990年低水平快速上升,2019年南亚达95.2%(91.4-97.7)。
- 第三代头孢菌素耐药伤寒在整个流行区域研究期间保持低水平,但巴基斯坦2019年达61.0%(58.0-63.8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Enteric fever, a systemic infection caused by Salmonella enterica serovars Typhi and Paratyphi A, remains a major cause of morbidity and mortality in low-income and middle-income countries. Enteric fever is preventable through the provision of clean water and adequate sanitation and can be successfully treated with antibiotics. However, high levels of antimicrobial resistance (AMR) compromise the effectiveness of treatment. We provide estimates of the prevalence of AMR S Typhi and S Paratyphi A in 75 endemic countries, including 30 locations without data. METHODS: We used a Bayesian spatiotemporal modelling framework to estimate the percentage of multidrug resistance (MDR), fluoroquinolone non-susceptibility (FQNS), and third-generation cephalosporin resistance in S Typhi and S Paratyphi A infections for 1403 administrative level one districts in 75 endemic countries from 1990 to 2019. We incorporated data from a comprehensive systematic review, public health surveillance networks, and large multicountry studies on enteric fever. Estimates of the prevalence of AMR and the number of AMR infections (based on enteric fever incidence estimates by the Global Burden of Diseases study) were produced at the country, super-region, and total endemic area level for each year of the study. FINDINGS: We collated data from 601 sources, comprising 184 225 isolates of S Typhi and S Paratyphi A, covering 45 countries over 30 years. We identified a decline of MDR S Typhi in south Asia and southeast Asia, whereas in sub-Saharan Africa, the overall prevalence increased from 6·0% (95% uncertainty interval 4·3-8·0) in 1990 to 72·7% (67·7-77·3) in 2019. Starting from low levels in 1990, the prevalence of FQNS S Typhi increased rapidly, reaching 95·2% (91·4-97·7) in south Asia in 2019. This corresponded to 2·5 million (1·5-3·8) MDR S Typhi infections and 7·4 million (4·7-11·3) FQNS S Typhi infections in endemic countries in 2019. The prevalence of third-generation cephalosporin-resistant S Typhi remained low across the whole endemic area over the study period, except for Pakistan where prevalence of third-generation cephalosporin resistance in S Typhi reached 61·0% (58·0-63·8) in 2019. For S Paratyphi A, we estimated low prevalence of MDR and third-generation cephalosporin resistance in all endemic countries, but a drastic increase of FQNS, which reached 95·0% (93·7-96·1; 3·5 million [2·2-5·6] infections) in 2019. INTERPRETATION: This study provides a comprehensive and detailed analysis of the prevalence of MDR, FQNS, and third-generation cephalosporin resistance in S Typhi and S Paratyphi A infections in endemic countries, spanning the last 30 years. Our analysis highlights the increasing levels of AMR in this preventable infection and serves as a resource to guide urgently needed public health interventions, such as improvements in water, sanitation, and hygiene and typhoid fever vaccination campaigns. FUNDING: Fleming Fund, UK Department of Health and Social Care; Wellcome Trust; and Bill and Melinda Gates Foundation.
引用
- Estimating the subnational prevalence of antimicrobial resistant Salmonella enterica serovars Typhi and Paratyphi A infections in 75 endemic countries, 1990-2019: a modelling study. Lancet Glob Health. 2024. PMID: 38365414. doi:10.1016/S2214-109X(23)00585-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。